Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
This study is not yet open for participant recruitment.
Verified June 2012 by British Columbia Cancer Agency
British Columbia Cancer Agency
Information provided by (Responsible Party):
Kim Chi, British Columbia Cancer Agency
First received: June 25, 2012
Last updated: June 27, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is not yet open for participant recruitment.|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011 Sep;186(3):889-97. Epub 2011 Jul 23.